Investors Buy Large Volume of Put Options on Evelo Biosciences (NASDAQ:EVLO)

Evelo Biosciences, Inc. (NASDAQ:EVLO) was the recipient of unusually large options trading on Wednesday. Traders bought 1,885 put options on the company. This represents an increase of approximately 1,101% compared to the typical daily volume of 157 put options.

Analyst Upgrades and Downgrades

Separately, TD Cowen reissued a “market perform” rating on shares of Evelo Biosciences in a report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. According to MarketBeat, Evelo Biosciences has a consensus rating of “Hold” and an average target price of $63.33.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Shay Capital LLC acquired a new stake in Evelo Biosciences during the 4th quarter worth about $30,000. Barclays PLC grew its stake in shares of Evelo Biosciences by 654.2% in the 4th quarter. Barclays PLC now owns 22,641 shares of the company’s stock valued at $36,000 after buying an additional 19,639 shares during the period. Walleye Capital LLC acquired a new stake in shares of Evelo Biosciences in the 1st quarter valued at about $38,000. Boothbay Fund Management LLC acquired a new stake in shares of Evelo Biosciences in the 4th quarter valued at about $85,000. Finally, Man Group plc bought a new position in Evelo Biosciences in the 4th quarter valued at about $85,000. 50.69% of the stock is currently owned by institutional investors.

Evelo Biosciences Price Performance

NASDAQ EVLO opened at $0.45 on Thursday. The business has a fifty day moving average price of $2.66 and a two-hundred day moving average price of $4.29. Evelo Biosciences has a fifty-two week low of $0.30 and a fifty-two week high of $48.00. The stock has a market capitalization of $8.43 million, a PE ratio of -0.03 and a beta of 1.81.

Evelo Biosciences (NASDAQ:EVLO) last released its earnings results on Monday, August 14th. The company reported ($3.55) earnings per share for the quarter, topping the consensus estimate of ($4.33) by $0.78.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc, a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.